Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials

Area of Science:

• Pharmacology and Clinical Trials
• Cardiovascular Medicine
• Thrombosis and Hemostasis

Background:

• Previous Phase II trials of asundexian were limited in their ability to detect significant differences in bleeding events.
• Understanding the safety profile of asundexian is crucial, especially in comparison to existing anticoagulants.

Purpose of the Study:

• To provide precise estimates of asundexian's effects on major and clinically relevant nonmajor bleeding events.
• To compare bleeding rates of asundexian against active controls (apixaban) and placebo.
• To identify common bleeding sites and explore the relationship between asundexian exposure and bleeding risk.

Main Methods:

• A pooled analysis of three Phase II clinical trials involving asundexian.
• Inclusion of patients with atrial fibrillation (AF), recent acute myocardial infarction (AMI), or stroke.
• Bleeding events classified using the International Society on Thrombosis and Hemostasis (ISTH) criteria.

Main Results:

• In AF patients, asundexian (20mg and 50mg) demonstrated fewer major/CRNM and all bleeding events compared to apixaban.
• In AMI/stroke patients, asundexian (10mg, 20mg, 50mg) showed similar rates of major/CRNM and all bleeding events compared to placebo.
• The most frequent bleeding sites included gastrointestinal, respiratory, urogenital, and skin; no significant association was found between asundexian exposure and major/CRNM bleeding.

Conclusions:

• Phase II data suggest asundexian may offer improved safety over apixaban and comparable safety to placebo.
• The findings highlight the potential of asundexian as a safer anticoagulant option.
• Efficacy data are pending results from ongoing Phase III trials.